Jim Simons Erasca, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Erasca, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,291,000 shares of ERAS stock, worth $3.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,291,000

Previous 1,575,100 18.04%

Holding current value

$3.49 Million

Previous $3.72 Million 5.19%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.17 - $3.28 $616,497 - $931,848	-284,100 Reduced 18.04%	1,291,000 $3.52 Million
Q2 2024 Aug 09, 2024	SELL	$1.79 - $2.63 $101,135 - $148,595	-56,500 Reduced 3.46%	1,575,100 $3.72 Million
Q1 2024 May 13, 2024	SELL	$1.67 - $2.55 $629,423 - $961,094	-376,900 Reduced 18.77%	1,631,600 $3.36 Million
Q4 2023 Feb 13, 2024	BUY	$1.67 - $2.49 $2.11 Million - $3.15 Million	1,266,400 Added 170.65%	2,008,500 $4.28 Million
Q3 2023 Nov 14, 2023	SELL	$1.97 - $2.91 $806,912 - $1.19 Million	-409,600 Reduced 35.56%	742,100 $1.46 Million
Q2 2023 Aug 11, 2023	SELL	$2.57 - $3.3 $786,394 - $1.01 Million	-305,990 Reduced 20.99%	1,151,700 $3.18 Million
Q1 2023 May 12, 2023	BUY	$2.74 - $4.44 $3.02 Million - $4.9 Million	1,103,115 Added 311.11%	1,457,690 $4.39 Million
Q4 2022 Feb 13, 2023	BUY	$3.89 - $8.57 $1.38 Million - $3.04 Million	354,575 New	354,575 $1.53 Million
Q2 2022 Aug 12, 2022	BUY	$4.58 - $8.72 $533,570 - $1.02 Million	116,500 Added 549.53%	137,700 $767,000
Q1 2022 May 13, 2022	BUY	$8.6 - $15.48 $182,320 - $328,176	21,200 New	21,200 $182,000

Others Institutions Holding ERAS

# of Institutions

141

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $330M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account